BR0213293A - Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia - Google Patents

Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia

Info

Publication number
BR0213293A
BR0213293A BR0213293-1A BR0213293A BR0213293A BR 0213293 A BR0213293 A BR 0213293A BR 0213293 A BR0213293 A BR 0213293A BR 0213293 A BR0213293 A BR 0213293A
Authority
BR
Brazil
Prior art keywords
tfpi
septicemia
analog
treatment
tfpi analog
Prior art date
Application number
BR0213293-1A
Other languages
English (en)
Inventor
Alba A Creasey
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of BR0213293A publication Critical patent/BR0213293A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"USO DE TFPI OU DE UM ANáLOGO DE TFPI NO TRATAMENTO DE SEPTICEMIA". Método para tratar profilaticamente e terapeuticamente septicemia e choque séptico, que envolve a administração de inibidor de via de fator (TFPI) ou um análogo de TFPI a pacientes que sofrem de septicemia ou outras condições inflamatórias. Os métodos envolvem o uso de infusão intravenosa contínua de TFPI ou um análogo de TFPI em baixas doses para evitar efeitos colaterais adversos.
BR0213293-1A 2001-10-15 2002-10-15 Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia BR0213293A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32880601P 2001-10-15 2001-10-15
PCT/US2002/032625 WO2003055442A2 (en) 2001-10-15 2002-10-15 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
BR0213293A true BR0213293A (pt) 2004-12-21

Family

ID=23282520

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0213292-3A BR0213292A (pt) 2001-10-15 2002-10-15 tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
BR0213293-1A BR0213293A (pt) 2001-10-15 2002-10-15 Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0213292-3A BR0213292A (pt) 2001-10-15 2002-10-15 tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)

Country Status (17)

Country Link
US (2) US7674769B2 (pt)
EP (2) EP1446138A4 (pt)
JP (5) JP2005506345A (pt)
KR (2) KR20050036867A (pt)
CN (2) CN1604790A (pt)
AU (2) AU2002365131B2 (pt)
BR (2) BR0213292A (pt)
CA (2) CA2463655A1 (pt)
EA (2) EA200400549A1 (pt)
HU (2) HUP0501111A2 (pt)
IL (2) IL161407A0 (pt)
IS (2) IS7224A (pt)
MX (2) MXPA04003547A (pt)
NO (2) NO20041997D0 (pt)
PL (2) PL374506A1 (pt)
WO (2) WO2003032904A2 (pt)
ZA (2) ZA200403601B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
JP2008500942A (ja) * 2003-01-08 2008-01-17 カイロン コーポレイション 組織因子経路インヒビターまたは組織因子経路インヒビター改変体を含有する安定化凍結乾燥組成物
EP1654283B1 (en) 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Improved method of purifying tfpi and tfpi analogs
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
AU2006236698A1 (en) * 2005-04-15 2006-10-26 Abla Creasey Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(TFPI)
WO2006122139A2 (en) * 2005-05-06 2006-11-16 Novartis Ag Use of tfpi to treat severe bacterial infections
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
US8088728B2 (en) * 2005-06-24 2012-01-03 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
AU2006272653A1 (en) * 2005-07-22 2007-02-01 Novartis Ag TFPI fragments as anti-microbial agents
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
AU2012285875B2 (en) 2011-07-18 2016-11-10 Morphosys Ag Use of c-Fms antagonists
US9592275B2 (en) * 2011-11-15 2017-03-14 Asahi Kasei Pharma Corporation Medicament for therapeutic treatment and/or improvement of sepsis
WO2014167088A1 (en) 2013-04-12 2014-10-16 Morphosys Ag Antibodies targeting m-csf
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
WO2023142096A1 (en) * 2022-01-30 2023-08-03 Westlake University Composition and method for preventing and/or treating clostridioides difficile infections caused by clade 2 strains

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
EP0179861A1 (en) 1984-04-19 1986-05-07 Agracetus Methods and vectors for transformation of plant cells
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5110730A (en) 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK412389D0 (da) 1989-01-19 1989-01-19 Novo Nordisk As Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK148890D0 (da) 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
JPH0733336B2 (ja) 1990-08-27 1995-04-12 モンサント カンパニー Ｌａｃｉと硫酸化ポリサッカライドとの組み合わせ抗凝固剤
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
USRE36476E (en) 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US5276015A (en) 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
ATE187648T1 (de) 1992-06-01 2000-01-15 Chiron Corp Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen
KR950701820A (ko) 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
JP3761914B2 (ja) * 1994-11-17 2006-03-29 財団法人化学及血清療法研究所 アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5612363A (en) 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US5885781A (en) 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
PT1602667E (pt) * 1995-06-07 2007-07-13 Searle Llc Formulação aquosa que compreende tfpi e agentes de solubilização
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
JP4129994B2 (ja) 1996-03-25 2008-08-06 財団法人化学及血清療法研究所 組織因子凝固系インヒビター含有血管新生阻害剤
US5977057A (en) 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
AU6042298A (en) * 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
BR9809304B1 (pt) 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
IL142248A0 (en) 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
ES2195655T3 (es) 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
AU4683299A (en) * 1999-06-11 2001-01-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection
WO2000077246A2 (en) 1999-06-14 2000-12-21 Novo Nordisk A/S A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
US6294648B1 (en) 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
WO2001024814A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
AU2908501A (en) 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
KR20020081330A (ko) 2000-02-16 2002-10-26 노오쓰웨스턴 유니버시티 폴리펩토이드 폐 계면활성제
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
DE60217835D1 (en) 2001-02-28 2007-03-15 John H Griffin Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c
WO2002099098A1 (en) 2001-04-04 2002-12-12 American Diagnostica, Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
US20020198138A1 (en) 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
ZA200403690B (en) 2005-03-08
CA2463655A1 (en) 2003-04-24
IL161407A0 (en) 2004-09-27
EP1446138A2 (en) 2004-08-18
EA200400549A1 (ru) 2005-02-24
NO20041997D0 (no) 2004-05-14
HUP0501111A2 (en) 2007-12-28
US20030139339A1 (en) 2003-07-24
AU2002365131B2 (en) 2007-03-01
PL372138A1 (en) 2005-07-11
CA2463738A1 (en) 2003-07-10
JP2010006839A (ja) 2010-01-14
WO2003032904A2 (en) 2003-04-24
IL161408A0 (en) 2004-09-27
IS7223A (is) 2004-04-15
MXPA04003547A (es) 2004-07-22
EP1446138A4 (en) 2007-03-14
JP2005515214A (ja) 2005-05-26
US20030139340A1 (en) 2003-07-24
CN1604790A (zh) 2005-04-06
NO20041996D0 (no) 2004-05-14
JP2006008704A (ja) 2006-01-12
JP2005506345A (ja) 2005-03-03
KR20040040489A (ko) 2004-05-12
EP1446140A2 (en) 2004-08-18
ZA200403601B (en) 2006-06-28
MXPA04003548A (es) 2004-07-22
JP2006008706A (ja) 2006-01-12
WO2003055442A2 (en) 2003-07-10
CN1604787A (zh) 2005-04-06
US7674769B2 (en) 2010-03-09
WO2003032904A3 (en) 2004-03-04
HUP0500472A2 (hu) 2005-08-29
PL374506A1 (en) 2005-10-31
EA200400548A1 (ru) 2005-06-30
EP1446140A4 (en) 2007-03-07
IS7224A (is) 2004-04-15
BR0213292A (pt) 2006-05-23
KR20050036867A (ko) 2005-04-20
AU2002340183B2 (en) 2008-11-13
AU2002365131A1 (en) 2003-07-15
WO2003055442A3 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
BR0213293A (pt) Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
MEP28208A (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
NO931886L (no) Anvendelse av aica ribocid-forbindelser for behandling/prevensjon av vevskader som skyldes nedsatt blodstroemning
BR0015039A (pt) Método para administrar um inibidor fosfodiesterase 4
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
SE9902597D0 (sv) New use
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
TNSN06295A1 (en) Treatment of severe community - acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
DK0651645T3 (da) Fremgangsmåde og medikament til inhibering af neutrofil elastase og cathepsin G
CA2403674A1 (en) The use of t3 for treating congestive heart failure
TNSN07386A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
BR0307196A (pt) Idraparinux (sanorg 34006) para tratamento e profilaxia secundária de eventos tromboembólicos venosos em pacientes com trombose venosa profunda
PT1171160E (pt) Metodo e meios para tratar o sindroma pos poliomielite
CO5251402A1 (es) Metodo pra tratar el mal de parkinson a traves de la administracion de (-)-5-ceto-2-n,n-di-n-propilamino tetrahidrotetralina
AR022475A1 (es) Metodo para la prevencion o reduccion de eventos cardiovasculares asociados con intervencion coronaria.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]